Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin.
BACKGROUND
Previous studies demonstrated the EGF-targeted phagemid particles carrying siRNA against Akt could be expressed efficiently in the presence of hydroxycamptothecin (HCPT). However, no significant cell growth inhibition was obtained. This study was to further investigate whether the EGF-targeted phagemid particles carrying siRNA would be a promising tool for anti-cancer siRNA delivery.


RESULTS
We found that pSi4.1-siFAK phagemid particles could significantly inhibit the expression of focal adhesion kinase in the HCPT-treated cells. Moreover, we also observed that the particles could potently suppress cell growth and cell invasion.


CONCLUSIONS
These results indicated that EGF-targeted phagemid particles might be a promising tool for anti-cancer siRNA delivery in the presence of HCPT.
Cai
Xiu-Mei
XM
Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, PR China. caixm06@gmail.com
Xie
Hai-Long
HL
Liu
Ming-Zhu
MZ
Zha
Xi-Liang
XL
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001435:Bacteriophages / Q000235:genetics; D001483:Base Sequence; D002166:Camptothecin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D003131:Combined Modality Therapy; D004815:Epidermal Growth Factor / Q000235:genetics; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D005822:Genetic Vectors; D006801:Humans; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics
D000972:Antineoplastic Agents, Phytogenic; D034741:RNA, Small Interfering; D004815:Epidermal Growth Factor; C028098:10-hydroxycamptothecin; D051416:Focal Adhesion Protein-Tyrosine Kinases; D002166:Camptothecin
Biotechniques. 2006 Dec;41(6):706-7
17191613
Cancer Gene Ther. 1998 Nov-Dec;5(6):357-64
9917090
Lung Cancer. 2006 Sep;53(3):263-71
16842883
Biochem Biophys Res Commun. 1999 Nov 2;264(3):921-8
10544031
FASEB J. 1999 Apr;13(6):727-34
10094933
J Mol Biol. 1999 Apr 30;288(2):203-11
10329137
Anticancer Res. 2004 Nov-Dec;24(6):3899-905
15736429
Biotechniques. 2005 Oct;39(4):493-7
16235561
Int J Cancer. 2005 Dec 20;117(6):905-12
15986432
Biotechnol Prog. 2006 May-Jun;22(3):626-30
16739942
Oncogene. 2006 Jul 27;25(32):4429-40
16547501
Mol Cell Biochem. 2000 Apr;207(1-2):49-55
10888226
Nat Biotechnol. 2001 Jan;19(1):75-8
11135557
Virology. 2001 Mar 30;282(1):102-12
11259194
Cancer Res. 2002 Feb 15;62(4):977-81
11861367
Hum Pathol. 2003 Mar;34(3):240-5
12673558
Am J Pathol. 2004 Oct;165(4):1087-95
15466376
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10879-84
9380728
Head Neck. 1998 Dec;20(8):745-52
9790298
Acta Pharmacol Sin. 2008 Apr;29(4):437-42
18358089
Hum Gene Ther. 1998 Nov 1;9(16):2393-9
9829538